Targeting XPO1 for fighting relapsed/refractory diseases: The research progress of XPO1 inhibitors

Ye-Qin Li; Zhou Fang; Wen Zhang; Guo-Wu Rao; Quan Zheng

doi:10.1016/j.bioorg.2024.108073

Targeting XPO1 for fighting relapsed/refractory diseases: The research progress of XPO1 inhibitors

Bioorg Chem. 2024 Dec 16:154:108073. doi: 10.1016/j.bioorg.2024.108073. Online ahead of print.

Authors

Ye-Qin Li¹, Zhou Fang¹, Wen Zhang¹, Guo-Wu Rao², Quan Zheng³

Affiliations

¹ College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 310014, PR China.
² College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 310014, PR China. Electronic address: rgw@zjut.edu.cn.
³ Core Facility, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, 324000, PR China. Electronic address: zhengquan@wmu.edu.cn.

PMID: 39708554
DOI: 10.1016/j.bioorg.2024.108073

Abstract

XPO1 is an influential member of the nuclear transporter protein family. The proteins and RNA transported by XPO1 are related to the occurrence and development of many diseases, including refractory tumor diseases and various viral infectious diseases. XPO1 is upregulated in many malignant tumors and is associated with poor prognosis. This article reviews the anti-tumor and anti-viral mechanisms of XPO1, and summarizes the biomarkers that predict the response to XPO1 inhibitors and the research progress of XPO1 as a biomarker in different diseases. In addition, we also summarize the research status of XPO1 inhibitors, and discuss the structure-activity relationship of preclinical inhibitors targeting XPO1 and the research status of XPO1 inhibitor resistance mechanisms.

Keywords: Biomarker; Molecular mechanism; SINE; Structure-activity relationship; XPO1.

Publication types

Review